Loading clinical trials...
Loading clinical trials...
REBECCA Real-world Early BrEast CanCer mAnagement REBECCA. a French National Multicentric Real-world Study of Early Breast Cancer Patients
This is a French observational, national, multicenter prospective cohort study of patients with HER2-negative eBC treated with olaparib at their physician's discretion.
The purpose to this observational study is to evaluate the rate of completion of adjuvant Olaparib treatment for HER2-negative early breast cancer patients in France.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Agen, France
Research Site
Argenteuil, France
Research Site
Avignon, France
Research Site
Beauvais, France
Research Site
Beuvry, France
Research Site
Bezannes, France
Research Site
Caen, France
Research Site
Chambray-lès-Tours, France
Research Site
Champigny-sur-Marne, France
Research Site
Clermont-Ferrand, France
Start Date
December 30, 2024
Primary Completion Date
January 31, 2028
Completion Date
January 31, 2028
Last Updated
January 21, 2026
126
ESTIMATED participants
AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479information.center@astrazeneca.comLead Sponsor
AstraZeneca
NCT05245812
NCT05673200
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions